Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Oruka Therapeutics Inc. Common StockTrade
Rivian Automotive, Inc.Trade

Price performance (Past 24H)

Key statistics

Oruka Therapeutics Inc. Common Stock vs Rivian Automotive, Inc. — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $76.8 (market cap $5.08B), while Rivian Automotive, Inc. trades at $12.85 (market cap $18.75B). The key difference: Rivian Automotive, Inc. is far larger — about 3.7× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Rivian Automotive, Inc. for 61 Days on average.

ORKARIVN
Market Cap
$5.08B$18.75B
Volume
685,27623,581,407
Sector
HealthConsumer Cyclical
52-Week High
$113.08$22.45
52-Week Low
$26.19$12.50
Typical Hold Time
0 Days61 Days
Enterprise Value
$4.21B$18.79B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Oruka Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Rivian Automotive, Inc.

Rivian (RIVN) trades at $13.37, down 1.26% as investors react to mixed Q3 2026 delivery results. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal improving revenue trends ($5.39B in 2025) but persistent losses (-$3.65B net income). Recent news highlights record vehicle deliveries of 19,248 units in Q3 2026 but disappointment over unchanged full-year guidance.

The outlook remains challenging with significant cash burn and negative margins, though analyst consensus suggests 26% upside to the $16.89 price target. Key risks include execution on R2 production ramp, competitive EV market pressures, and path to profitability. The stock trades near analyst low targets, reflecting cautious optimism about Rivian's scaling potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ORKA
100% Buy0% Sell
Avg holding period · 0 Days
RIVN
65% Buy35% Sell
Avg holding period · 61 Days

Top news

Latest headlines on both assets

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →

About Rivian Automotive, Inc.

Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.

Read more on RIVN →